EMEA-001671-PIP01-14 - paediatric investigation plan

abrilumab

Key facts

• Active substance:
  abrilumab
• Therapeutic area:
  Gastroentology-Hepatology
• Decision number:
  P/0027/2016
• PIP number:
  EMEA-001671-PIP01-14
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  • Treatment of ulcerative colitis
  • Treatment of Crohn's disease
• Route(s) of administration:
  Subcutaneous use
• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  29/01/2016
• Compliance check done:
  No

Decision

P/0027/2016: EMA decision of 29 January 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for abrilumab (EMEA-001671-PIP01-14)

Adopted Reference Number: EMA/2820/2016